{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharynx+Cancer&page=2", "query": { "condition": "Pharynx Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharynx+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T06:46:32.895Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03254927", "title": "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "CDX-3379 and cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-03-27", "completion_date": "2020-12-16", "has_results": true, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 10, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03254927" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT00918762", "title": "Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Perioperative/Postoperative Complications", "Precancerous Condition" ], "interventions": [ { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "diagnostic endoscopic surgery", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "therapeutic endoscopic surgery", "type": "PROCEDURE" }, { "name": "transoral robotic surgery", "type": "PROCEDURE" }, { "name": "video-assisted surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2009-05", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00918762" }, { "nct_id": "NCT03618134", "title": "Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Human Papillomavirus Positive", "Oropharyngeal Squamous Cell Carcinoma", "p16 Positive Neoplastic Cells Present", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Modified Radical Neck Dissection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Transoral Robotic Surgery", "type": "PROCEDURE" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2018-10-04", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618134" }, { "nct_id": "NCT06445114", "title": "Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Cancer", "Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zachary Zumsteg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-05-12", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 4, "location_summary": "Beverly Hills, California • Los Angeles, California • Tarzana, California + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445114" }, { "nct_id": "NCT03049358", "title": "Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage 0 Nasopharyngeal Carcinoma", "Stage 0 Paranasal Sinus Cancer", "Stage I Nasopharyngeal Carcinoma", "Stage I Paranasal Sinus Cancer", "Stage II Nasopharyngeal Carcinoma", "Stage II Paranasal Sinus Cancer", "Stage IIA Nasopharyngeal Carcinoma", "Stage IIB Nasopharyngeal Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage III Paranasal Sinus Cancer", "Stage IV Nasopharyngeal Carcinoma", "Stage IV Paranasal Sinus Cancer", "Stage IVA Nasopharyngeal Carcinoma", "Stage IVA Paranasal Sinus Cancer", "Stage IVB Nasopharyngeal Carcinoma", "Stage IVB Paranasal Sinus Cancer", "Stage IVC Nasopharyngeal Carcinoma", "Stage IVC Paranasal Sinus Cancer" ], "interventions": [ { "name": "Physiologic Testing", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sham Intervention", "type": "PROCEDURE" }, { "name": "Therapeutic Procedure", "type": "PROCEDURE" }, { "name": "rose essential oil", "type": "OTHER" }, { "name": "lemon essential oil", "type": "OTHER" }, { "name": "clove essential oil", "type": "OTHER" }, { "name": "eucalyptus essential oil", "type": "OTHER" }, { "name": "canola oil placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2016-12", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2019-02-05", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049358" }, { "nct_id": "NCT07124000", "title": "DESTINY-PANTUMOUR04", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma (NOS)", "Anal Cancer", "Bladder Cancer", "Cervical Cancer", "Endometrial Cancer", "Esophageal Cancer", "Gall Bladder Cancer", "Gastrointestinal Stromal Tumour", "Head and Neck Cancer", "Liver Cancer", "Melanoma", "Mouth Cancer", "Nasopharangeal Cancer", "Neuroendocrine, Gastrointestinal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cell Carcinoma", "Salivary Gland Cancer", "Sarcoma", "Small Cell Lung Cancer", "Testicular Cancer", "Throat Cancer", "Thyroid Cancer", "Urethral Cancer", "Vaginal Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 100, "start_date": "2025-09-18", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bullhead City", "state": "Arizona" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07124000" }, { "nct_id": "NCT05563272", "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Glioblastoma Multiforme", "Cholangiocarcinoma", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Soft Tissue Sarcoma", "Gastric Adenocarcinoma", "Malignant Mesothelioma (MM)", "Von Hippel Lindau", "Bladder Cancer", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 11, "start_date": "2023-06-06", "completion_date": "2025-05-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563272" }, { "nct_id": "NCT00592501", "title": "Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Proton/Photon Radiotherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-10", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00592501" }, { "nct_id": "NCT00516087", "title": "LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Genetically modified CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 23, "start_date": "2007-08", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-05-22T06:46:32.895Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516087" } ] }